Kenya’s Ministry of Health has announced a broad regulatory overhaul aimed at curbing counterfeit and substandard medicines, requiring pharmaceutical imports to comply with strict digital identification rules beginning in January.
The framework, unveiled during the Kenya Health Summit in Nairobi, requires imported medical products to carry unique serialized digital identifiers. Regulators, pharmacists and consumers will be able to use a centralized track-and-trace system to verify products and monitor their movement through the pharmaceutical supply chain.
Kenya’s new framework will require imported medicines to carry unique digital fingerprints that can be verified through a blockchain-backed tracking system, creating a digital record from manufacture through distribution to the point of dispensing.
The initiative is intended to address a long-standing counterfeit medicine problem that has been facilitated by porous borders within the East African Community. Investigations by the Pharmacy and Poisons Board have identified falsified antiretroviral medicines, rapid HIV testing kits and lifestyle drugs circulating through informal pharmacies and other unregulated outlets in major cities including Nairobi and Mombasa.
Digital tracking targets counterfeit supply chains
Under the proposed system, each pharmaceutical product would receive a serialized digital identity that can be checked at different stages of the supply chain. The technology is expected to create a tamper-resistant record showing the movement of a medicine from its manufacturing location to its final point of distribution.
The framework is modeled in part on serialization and pharmaceutical tracking systems used in developed markets. The government intends to use cryptographic verification to distinguish legitimate products from those that enter the country outside approved channels.
Medicines that fail the required verification process could be flagged for enforcement action. The framework would enable authorities, including the Kenya Revenue Authority and border control agencies, to identify potentially counterfeit or unauthorized products during importation and distribution.
The system is also expected to improve visibility for pharmacists and consumers. Rather than relying solely on packaging or conventional documentation, users could verify a product’s digital identity through the centralized platform.
Counterfeit medicines threaten health and industry
Kenyan authorities view the counterfeit medicine trade as both a public health and economic concern. Substandard medicines can expose patients to ineffective treatment, while falsified products can contain incorrect ingredients or inadequate quantities of active pharmaceutical substances.
The problem also contributes to antimicrobial resistance, particularly when patients receive antibiotics that do not contain sufficient therapeutic doses. Health Cabinet Secretary Deborah Barasa has linked stronger medicine verification to efforts to reduce the growing burden of antimicrobial resistance.
The World Health Organization has estimated that about one in 10 medical products in low- and middle-income countries is substandard or falsified, highlighting the scale of the challenge facing regulators and healthcare systems.
The government expects the system to strengthen medicine safety while helping authorities identify counterfeit products before they reach pharmacies, clinics and patients.
The counterfeit trade also creates challenges for legitimate pharmaceutical manufacturers. Kenya’s pharmaceutical industry contributes an estimated KSh 40 billion annually to the country’s economy, while multinational manufacturers have identified counterfeiting and intellectual property violations as obstacles to expanding local production.
Those concerns are particularly relevant as Kenya seeks to develop pharmaceutical manufacturing centers in areas such as Konza and Tatu City. Stronger supply-chain controls could improve confidence among manufacturers considering investment in local production and distribution.
Importers prepare for January deadline
With the January implementation deadline approaching, pharmaceutical importers and domestic distributors are working to connect their inventory management systems with the Ministry of Health’s digital gateway.
The transition is expected to require changes in inventory management, product identification and supply-chain reporting. Companies will need to ensure that imported medicines receive the required digital identifiers and remain traceable throughout distribution.
The digital track-and-trace framework could establish a new model for pharmaceutical regulation in Kenya by combining product serialization, blockchain-backed records and real-time verification across the medicine supply chain.
If implemented effectively, the system could provide regulators with greater visibility into pharmaceutical imports while giving healthcare providers and consumers an additional mechanism for confirming product authenticity. Kenya’s approach could also provide a potential regulatory template for other African markets facing similar counterfeit medicine and supply-chain challenges.
